Survey of Inhibitors in Plasma-Product Exposed Toddlers
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the immunogenicity of VWF/FVIII and of rFVIII
concentrates by determining the frequency of inhibitor development in previously untreated
patients (PUPs) or minimally blood component-treated (MBCTPs) in the first 50 EDs or in the
first 3 years from enrollment, whichever occurs first.
.